US0465131078 - Common Stock
ATARA BIOTHERAPEUTICS INC
NASDAQ:ATRA (4/26/2024, 5:49:57 PM)
After market: 0.69 0 (0%)0.69
-0.01 (-1.4%)
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 308 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.
ATARA BIOTHERAPEUTICS INC
2380 Conejo Spectrum St, Suite 200
Thousand Oaks CALIFORNIA 94080
P: 18056234244
CEO: Pascal Touchon
Employees: 308
Website: https://www.atarabio.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atara Biotherapeutics (NASDAQ:ATRA) just reported results for the fourth quarte...
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Atara Biotherapeutics (ATRA) said the FDA has cleared its application to begin Phase 1 testing of its immunotherapy ATA3219 for the treatment of lupus nephritis. Read more here.
Here you can normally see the latest stock twits on ATRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: